Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Decitabine/tetrahydrouridine - EpiDestiny/Novo Nordisk

Next Previous
Search
Drug Profile

Decitabine/tetrahydrouridine - EpiDestiny/Novo Nordisk

Alternative Names: Eclipse; EPI 01; NDec - EpiDestiny/Novo Nordisk; NN 7533; Tetrahydrouridine/decitabine

Latest Information Update: 23 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiDestiny
  • Developer EpiDestiny; Novo Nordisk
  • Class Antianaemics; Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Pyrimidinones; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA modification methylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sickle cell anaemia
  • No development reported Beta-thalassaemia; Cancer

Most Recent Events

  • 10 Jun 2024 Phase-I clinical trials in Sickle cell anaemia (In volunteers) in Germany (PO) prior to June 2024 (NCT06291285)
  • 10 Jun 2024 Novo Nordisk completes a phase I pharmacokinetics trial (In volunteers) in USA, Germany (PO) (NCT06291285)
  • 04 Mar 2024 Novo Nordisk plans a phase I pharmacokinetics trial (In volunteers) in USA, Germany (PO) (NCT06291285)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top